Fifth Third Wealth Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$230K Buy
6,068
+1,120
+23% +$51.6K 0.01% 925
2026
Q2
$237K Sell
4,948
-719
-13% -$30.9K 0.01% 839
2026
Q1
$208K Sell
5,667
-383
-6% -$18.1K 0.01% 781
2025
Q4
$308K Buy
6,050
+19
+0.3% +$972 0.01% 572
2025
Q3
$335K Buy
6,031
+603
+11% +$35.3K 0.01% 513
2025
Q2
$375K Buy
5,428
+1,249
+30% +$85K 0.02% 453
2025
Q1
$290K Buy
4,179
+1,064
+34% +$87.9K 0.02% 504
2024
Q4
$268K Sell
3,115
-544
-15% -$58.8K 0.01% 540
2024
Q3
$436K Buy
3,659
+1,873
+105% +$250K 0.03% 347
2024
Q2
$255K Buy
+1,786
New +$237K 0.02% 479

Other funds holding NVO

Fifth Third Wealth Advisors's NVO Position: Q3 2026 in Review

Fifth Third Wealth Advisors increased its Novo Nordisk (NVO) stake by 23% in Q3 2026, buying an estimated $51.6K and bringing the position to 6,068 shares worth $230K. The position accounts for 0.01% of the portfolio, ranked #925.

Fifth Third Wealth Advisors first reported a position in NVO in Q2 2024 and has held it in 10 quarters since. The position peaked at $436K in Q3 2024. 1,110 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • Fifth Third Wealth Advisors held 6,068 shares of Novo Nordisk worth $230K as of Q3 2026.
  • Fifth Third Wealth Advisors bought 1,120 Novo Nordisk shares in Q3 2026, an estimated $51.6K.
  • Novo Nordisk made up 0.01% of Fifth Third Wealth Advisors's portfolio in Q3 2026, its #925 holding.
  • Fifth Third Wealth Advisors first reported a position in Novo Nordisk in Q2 2024 and has held it in 10 quarters since.
  • Fifth Third Wealth Advisors's Novo Nordisk position peaked at $436K in Q3 2024.
  • 1,110 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Fifth Third Wealth Advisors's 13F filing for Q3 2026, filed 22 Oct 2026.